Finance
Gerresheimer slashes revenue guidance for 2025 in half
Published by Global Banking & Finance Review®
Posted on February 26, 2025
2 min readLast updated: January 25, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 26, 2025
2 min readLast updated: January 25, 2026
Gerresheimer slashes its 2025 revenue guidance by half, now projecting 3% to 5% growth. The Bormioli Pharma acquisition is included in this outlook.
By Isabel Demetz
(Reuters) - German packaging and medical equipment maker Gerresheimer, which makes pens used to inject weight loss drugs such as Novo Nordisk's Wegovy, halved its revenue guidance for 2025 on Wednesday.
The company now expects organic revenue growth in the range of 3% to 5% in 2025, down from the previous range of 7% to 10%. It, however, confirmed the guidance for adjusted core profit margin of around 22%.
The outlook includes the contribution from Bormioli Pharma, whose acquisition was finalised in December and is part of Gerresheimer's plans to create a new moulded glass business unit.
"The forecast was also influenced by the fact that we are seeing somewhat subdued demand in the cosmetics and food and beverage segments," a spokesperson told Reuters.
Additionally, Gerresheimer's customer SQ Innovation will be able to market a combination product with their body-worn drug pump only from October, shifting sales there as well, they added.
The company also cut its mid-term guidance for revenue, now expecting the figure to grow in a range of 8% to 10% at compounded annual growth rate, down from a previous projection for growth of equal or above 10%.
Gerresheimer also reported fourth-quarter results broadly in line with market expectations, driven by its plastics and devices division.
Adjusted core profit for the last quarter of 2024 came in at 126.7 million euros ($132.98 million), in line with analysts' expectation of 126.8 million euros in a company provided poll.
The primary packaging glass division showed first signs of recovery in the glass vial market in the fourth quarter, but destocking effects at pharmaceutical customers still weighed on the full year, the company said.
($1 = 0.9527 euros)
(Reporting by Isabel Demetz; Editing by Jacqueline Wong, Subhranshu Sahu and Louise Heavens)
Gerresheimer now expects organic revenue growth in the range of 3% to 5% for 2025, down from the previous range of 7% to 10%.
The forecast was influenced by subdued demand in the cosmetics and food and beverage segments, as well as a delay in marketing a combination product by customer SQ Innovation.
Gerresheimer reported fourth-quarter results that were broadly in line with market expectations, driven by its plastics and devices division, with adjusted core profit at 126.7 million euros.
Gerresheimer now expects mid-term revenue growth to be in the range of 8% to 10% at a compounded annual growth rate, down from a previous projection of 10% to 12%.
The acquisition of Bormioli Pharma, finalized in December, is part of Gerresheimer's plans to create a new moulded glass business unit.
Explore more articles in the Finance category
